Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with ...
Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a 17.2% complete response rate – – Antitumor ...
Zawya1 天
FDA approves Mirikizumab-mrkz for Crohn’s disease
Lilly has also submitted marketing applications for Mirikizumab-mrkz in Crohn’s disease around the globe, including in the ...
ImmunityBio, Inc. (IBRX) Stock: An Under $5 Gem with Biggest Upside Potential
We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this article, we are going to take a ...
News Medical5 天
Granzyme K+ CD8+ T-cells identified as key drivers of recurrent airway inflammation
Researchers identify a pathogenic subset of CD8+ memory T-cells that promote airway tissue inflammation and recurrent ...
The Pharma Letter5 天
AstraZeneca's Fasenra set to revolutionize COPD treatment
UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...
Wyoming News6 天
FDA Approves Omvoh for Moderately to Severely Active Crohn Disease
The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely ...